March 6, 2018

NCCN Guidelines® Panel: Non-Small Cell Lung Cancer

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed OPDIVO® (nivolumab) prescribing information and clinical data which supports the most recent label change, that occurred on March 5, 2018 to reflect the new dosing for nivolumab to 240mg administered intravenously every 2 weeks or 480mg administered intravenously every 4 weeks over 30 minutes.¹ This information is being sent to the NCCN® Non-Small Cell Lung Cancer Panel for your consideration.

Specific Changes: Request for the inclusion as a footnote to NSCL-27, NSCL-28, NSCL-I (1 OF 2), the following: nivolumab FDA approved dose is 240mg IV every 2 weeks or 480mg IV every 4 weeks administered over 30 minutes until disease progression or unacceptable toxicity.¹

FDA Clearance of OPDIVO® (nivolumab) (indication in Non-Small Cell Lung Cancer):

- OPDIVO is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Rationale: The Opdivo Prescribing Information was updated to reflect the new dosing of Opdivo to 240mg administered intravenously every 2 weeks or 480mg administered intravenously every 4 weeks over 30 minutes for all indications, except for metastatic colorectal cancer which is to be dosed at 240mg administered intravenously every 2 weeks over 30 minutes.¹ The dosing recommendations stated in the product label are different than the dose that was administered in the original protocol of the registrational clinical studies that support the current approved FDA indications.

As part of this submission, the published literature that support the pharmacokinetic analyses for the dosing of 240mg every 2 weeks, 480mg every 4 weeks, and a 30 minute infusion time are enclosed for your review.²⁻⁴


Thank you for your consideration.
Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company